Vaccine Therapy in Treating Patients With Liver Cancer

Inclusion Criteria:

* HLA-A\*0201 positive adults over the age of 18.
* Have HCC with a serum AFP determination \>30ng/ml.
* Both male and female patients may be enrolled.
* Karnofsky Performance Status greater than or equal to 70 percent.
* No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease.
* No previous evidence of opportunistic infection.
* Adequate baseline hematological function as assessed by the following laboratory values with 30 days prior to study entry:

  1. Hemoglobin \>9.0g/dl
  2. Platelets \>50000/mm3
  3. Absolute Neutrophil Count \>1,000/mm3
* Child-Pugh Class A or B for chronic liver disease.
* Ability to give informed consent.

Exclusion Criteria:

* Any congenital or acquired condition leading to inability to generate an immune response, including concomitant immune suppressive therapy.
* Concomitant steroid therapy or chemotherapy, or any of these other treatments \< 30 days before the first vaccination.
* Females of child-bearing potential must have negative serum beta-HCG pregnancy test (within Day -14 to Day 0).
* Acute infection: any acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed within 14 days prior to study treatment.
* HIV-infected patients.
* Patients with any underlying conditions which would contraindicate therapy with study treatment.
* Patients with organ allografts.
* O2 sat \<91% on room air; dyspnea at rest.